Following site-specific PEGylation, the clearance of A1A2A3-VWF variants were assessed in VWF−/− mice. (A) The clearance of A1-domain variants, (B) A2-domain variants and (C) A3-domain variants were all compared to non-PEGylated A1A2A3-WT. (D) PEGylation served to markedly increase the MRT of A1A2A3-VWF in a site-dependent manner. All data is graphed as mean values ± SEM, 3-5 mice per time point (* p <0.05, ** p <0.01, *** p <0.0001 respectively).